These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31298053)

  • 1. Drug prices and trends before and after requesting compulsory licenses: the Ecuadorian experience.
    Ortiz-Prado E; Cevallos-Sierra G; Teran E; Vasconez E; Borrero-Maldonado D; Ponce Zea J; Simbaña-Rivera K; Gómez-Barreno L
    Expert Opin Ther Pat; 2019 Aug; 29(8):653-662. PubMed ID: 31298053
    [No Abstract]   [Full Text] [Related]  

  • 2. Questions raised about whether compulsory licenses get best prices.
    Owens B
    Nat Med; 2015 Apr; 21(4):300. PubMed ID: 25849264
    [No Abstract]   [Full Text] [Related]  

  • 3. Access to critical medicines: When are compulsory licenses effective in price negotiations?
    Ramani SV; Urias E
    Soc Sci Med; 2015 Jun; 135():75-83. PubMed ID: 25957163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Looking inward: regional parallel trade as a means of bringing affordable drugs to Africa.
    Buckely M
    Seton Hall Law Rev; 2011; 41(2):625-69. PubMed ID: 21739760
    [No Abstract]   [Full Text] [Related]  

  • 5. Learning from practice: compulsory licensing cases and access to medicines.
    Stirner B
    Pharm Pat Anal; 2012 Nov; 1(5):555-75. PubMed ID: 24236925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Could international compulsory licensing reconcile tiered pricing of pharmaceuticals with the right to health?
    Ooms G; Forman L; Williams OD; Hill PS
    BMC Int Health Hum Rights; 2014 Dec; 14():37. PubMed ID: 25518744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compulsory licensing often did not produce lower prices for antiretrovirals compared to international procurement.
    Beall RF; Kuhn R; Attaran A
    Health Aff (Millwood); 2015 Mar; 34(3):493-501. PubMed ID: 25732501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioterrorism and patent rights: "compulsory licensure" and the case of Cipro.
    Resnik DB; DeVille KA
    Am J Bioeth; 2002; 2(3):29-39. PubMed ID: 12230852
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand.
    Supakankunti S; Janjaroen WS; Tangphao O; Ratanawijitrasin S; Kraipornsak P; Pradithavanij P
    Bull World Health Organ; 2001; 79(5):461-70. PubMed ID: 11417042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compulsory licensing in Canada and Thailand: comparing regimes to ensure legitimate use of the WTO rules.
    Lybecker KM; Fowler E
    J Law Med Ethics; 2009; 37(2):222-39. PubMed ID: 19493068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trans-Pacific Partnership Provisions in Intellectual Property, Transparency, and Investment Chapters Threaten Access to Medicines in the US and Elsewhere.
    Baker BK
    PLoS Med; 2016 Mar; 13(3):e1001970. PubMed ID: 26954325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intellectual property rights, compulsory licensing and the TRIPS agreement: some ethical issues.
    Schuklenk U
    Monash Bioeth Rev; 2003 Apr; 22(2):63-8. PubMed ID: 15069958
    [No Abstract]   [Full Text] [Related]  

  • 13. Compulsory licenses as a defense in pharmaceutical and biotech patent litigation.
    von Falck A
    Pharm Pat Anal; 2016 Sep; 5(6):351-353. PubMed ID: 27805479
    [No Abstract]   [Full Text] [Related]  

  • 14. Research on the pharmaceutical intellectual property protection and supervision of pharmacy administration.
    Xu Z; Chen W
    Pak J Pharm Sci; 2017 May; 30(3(Special)):1081-1087. PubMed ID: 28671085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
    Spectar JM
    Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
    [No Abstract]   [Full Text] [Related]  

  • 16. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compulsory licensure: the case of Cipro and beyond.
    Chakrabarty AM
    Am J Bioeth; 2002; 2(3):40. PubMed ID: 12230853
    [No Abstract]   [Full Text] [Related]  

  • 18. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 19. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
    Rosenberg ST
    Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.